HRP20201685T1 - Sastavi gama-hidroksibutirata i njihova upotreba za liječenje poremećaja - Google Patents
Sastavi gama-hidroksibutirata i njihova upotreba za liječenje poremećaja Download PDFInfo
- Publication number
- HRP20201685T1 HRP20201685T1 HRP20201685TT HRP20201685T HRP20201685T1 HR P20201685 T1 HRP20201685 T1 HR P20201685T1 HR P20201685T T HRP20201685T T HR P20201685TT HR P20201685 T HRP20201685 T HR P20201685T HR P20201685 T1 HRP20201685 T1 HR P20201685T1
- Authority
- HR
- Croatia
- Prior art keywords
- ghb
- gamma
- hydroxybutyrate
- pharmaceutical composition
- composition according
- Prior art date
Links
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 title claims 23
- 239000000203 mixture Substances 0.000 title claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000011575 calcium Substances 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- 239000011777 magnesium Substances 0.000 claims 3
- 239000011734 sodium Substances 0.000 claims 3
- 159000000007 calcium salts Chemical class 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 159000000003 magnesium salts Chemical class 0.000 claims 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 230000000813 microbial effect Effects 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Claims (10)
1. Farmaceutski sastav koji se sastoji od mješavine natrijeve soli gama-hidroksibutirata (Na•GHB), kalijeve soli gama-hidroksibutirata (K•GHB), magnezijeve soli gama-hidroksibutirata (Mg•(GHB)2), i kalcijeve soli gama-hidroksibutirata (Ca•(GHB)2),
gdje se natrijeva sol gama-hidroksibutirata (Na•GHB) nalazi u % mol. ekv. od 5% do 40%, kalijeva sol gama-hidroksibutirata (K•GHB) se nalazi u % mol. ekv. od 10% do 40%, magnezijeva sol gama-hidroksibutirata (Mg•(GHB)2) se nalazi u % mol. ekv. od 5% do 30%, i kalcijeva sol gama-hidroksibutirata (Ca•(GHB)2) se nalazi u % mol. ekv. od 20% do 80%.
2. Farmaceutski sastav prema zahtjevu 1, gdje su Na•GHB, K•GHB, Mg•(GHB)2, i Ca•(GHB)2 soli prisutne u odnosu % mol. ekv. redom od otprilike 8%:23%:21%:48%.
3. Farmaceutski sastav prema zahtjevu 1 ili 2, gdje je sastav formuliran kao tekući sastav, i gdje tekući sastav ima ukupnu koncentraciju soli GHB od oko 350 mg/mL do oko 650 mg/mL.
4. Farmaceutski sastav prema zahtjevu 3, gdje je ukupna koncentracija soli GHB oko 500 mg/mL.
5. Farmaceutski sastav prema zahtjevu 3 ili 4, gdje sastav ima pH oko 7.0 do oko 9.0.
6. Farmaceutski sastav prema zahtjevu 5, gdje sastav ima pH oko 7.3 do oko 8.5.
7. Farmaceutski sastav prema bilo kojem od zahtjeva 3 do 6, gdje je sastav kemijski stabilan i otporan je na rast mikroba, i gdje je sastav bez konzervansa.
8. Farmaceutski sastav prema zahtjevu 1 ili 2, gdje je sastav u čvrstoj formulaciji.
9. Farmaceutski sastav prema zahtjevu 8, gdje je čvrsta formulacija tableta, pilula, kapsula ili prašak.
10. Farmaceutski sastav prema zahtjevu 9, gdje je kapsula kapsula s oslobađanjem tokom vremena.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737695P | 2012-12-14 | 2012-12-14 | |
| EP17202548.8A EP3335709B1 (en) | 2012-12-14 | 2013-12-13 | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201685T1 true HRP20201685T1 (hr) | 2020-12-25 |
Family
ID=49596603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201685TT HRP20201685T1 (hr) | 2012-12-14 | 2020-10-19 | Sastavi gama-hidroksibutirata i njihova upotreba za liječenje poremećaja |
Country Status (26)
| Country | Link |
|---|---|
| US (9) | US8591922B1 (hr) |
| EP (3) | EP2931268B1 (hr) |
| JP (1) | JP6215347B2 (hr) |
| KR (1) | KR102180343B1 (hr) |
| CN (1) | CN105025892B (hr) |
| AU (1) | AU2013359114B2 (hr) |
| BR (1) | BR112015014007A2 (hr) |
| CA (1) | CA2894876C (hr) |
| CY (2) | CY1119918T1 (hr) |
| DK (2) | DK3335709T3 (hr) |
| ES (2) | ES2660056T3 (hr) |
| HK (1) | HK1215181A1 (hr) |
| HR (1) | HRP20201685T1 (hr) |
| HU (1) | HUE051060T2 (hr) |
| IL (1) | IL239355A (hr) |
| IN (1) | IN342829B (hr) |
| LT (1) | LT3335709T (hr) |
| MX (1) | MX366681B (hr) |
| NO (1) | NO3027826T3 (hr) |
| PL (1) | PL2931268T3 (hr) |
| PT (2) | PT3335709T (hr) |
| SG (1) | SG11201504637TA (hr) |
| SI (1) | SI3335709T1 (hr) |
| TR (1) | TR201802271T4 (hr) |
| TW (2) | TWI681770B (hr) |
| WO (1) | WO2014093791A1 (hr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120076865A1 (en) | 2010-03-24 | 2012-03-29 | Jazz Pharmaceuticals, Inc. | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances |
| US8591922B1 (en) | 2012-12-14 | 2013-11-26 | Jazz Pharmacuticals, Inc. | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
| ES2930848T3 (es) | 2015-09-23 | 2022-12-22 | Xwpharma Ltd | Profármacos de ácido gamma-hidroxibutírico, composiciones y usos de los mismos |
| FR3049463B1 (fr) | 2016-04-01 | 2019-07-05 | Debregeas Et Associes Pharma | Doses unitaires a liberation immediate de ghb ou de l'un de ses sels therapeutiquement acceptables administrees par voie orale et leur utilisation pour maintenir l'abstinence alcoolique |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11000498B2 (en) | 2016-07-22 | 2021-05-11 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US20180263936A1 (en) * | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| WO2019126214A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release |
| US11666546B2 (en) | 2017-12-18 | 2023-06-06 | Tris Pharma, Inc | GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system |
| WO2019126218A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release |
| AU2019383389A1 (en) | 2018-11-19 | 2021-05-06 | Jazz Pharmaceuticals Ireland Limited | Alcohol-resistant drug formulations |
| CA3127871A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US20210186907A1 (en) * | 2019-12-24 | 2021-06-24 | Jazz Pharmaceuticals Ireland Limited | Ghb dosing |
| TW202139986A (zh) * | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
| WO2022020621A1 (en) | 2020-07-24 | 2022-01-27 | XWPharma Ltd. | Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative |
| JP2023544420A (ja) | 2020-10-05 | 2023-10-23 | エックスダブリューファーマ リミテッド | ガンマ－ヒドロキシ酪酸誘導体の調節放出組成物 |
| WO2022076824A1 (en) | 2020-10-08 | 2022-04-14 | Jazz Pharmaceuticals Ireland Limited | Sodium oxybate to treat idiopathic hypersomnia |
| AU2021362222A1 (en) | 2020-10-16 | 2023-06-01 | Jazz Pharmaceuticals Ireland Limited | Treatment methods using ghb |
| JP2024511991A (ja) | 2021-03-19 | 2024-03-18 | エックスダブリューファーマ リミテッド | ガンマ－ヒドロキシ酪酸誘導体の組み合わされた放出製剤の薬物動態 |
| AU2022246286A1 (en) * | 2021-03-20 | 2023-09-07 | Alkem Laboratories Limited | A process for the preparation of mixed oxybate salts and polymorphs thereof |
| US11877992B1 (en) | 2021-06-07 | 2024-01-23 | Kelly Kathleen Spinelli | Gamma-hydroxybutyrate salts for the treatment of learning disorders |
| US11877993B1 (en) | 2021-06-23 | 2024-01-23 | Kelly Kathleen Spinelli | Gamma-hydroxybutyrate salts for the treatment of psychological disorders |
| EP4415701A1 (en) | 2021-10-11 | 2024-08-21 | Jazz Pharmaceuticals Ireland Limited | Method of administering oxybate |
| WO2023135150A1 (en) | 2022-01-11 | 2023-07-20 | Jazz Pharmaceuticals Ireland Limited | Method of administering oxybate |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2023205245A1 (en) * | 2022-04-21 | 2023-10-26 | Zevra Therapeutics, Inc. | Gamma-hydroxybutyrate delivering compounds and processes for making and using them |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB922029A (en) | 1960-05-19 | 1963-03-27 | Equilibre Biolog L | Therapeutic composition |
| US4374441A (en) | 1980-05-23 | 1983-02-22 | Book Covers, Inc. | Method of making a book cover and pocket element therefor |
| ZA814854B (en) | 1980-07-17 | 1982-07-28 | J Klosa | Nonhygroscopic salts of 4-hydroxybutryric acid, methods of their production and pharmaceutical preparations containing these salts |
| EP0044801B1 (de) | 1980-07-17 | 1984-02-15 | Josef Dr. Klosa | Nichthygroskopische Salze der 4-Hydroxybuttersäure, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Mittel |
| EP0235408B1 (en) | 1984-08-06 | 1991-01-09 | The University Of Toronto Innovations Foundation | Pharmaceutical composition and treatment |
| US4738985A (en) | 1986-03-19 | 1988-04-19 | The University Of Toronto Innovations Foundations | Pharmaceutical composition and treatment |
| IT1217783B (it) | 1988-06-03 | 1990-03-30 | Farmaceutico Ct S R L Lab | Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative |
| JP2564690B2 (ja) | 1990-06-14 | 1996-12-18 | 三省製薬 株式会社 | メラニン生成抑制外用剤 |
| DE4113984C2 (de) | 1991-04-29 | 2002-05-08 | Koehler Chemie Dr Franz | Salze der 4-Hydroxy-Buttersäure |
| IT1271403B (it) | 1993-03-26 | 1997-05-28 | Ct Lab Farm Srl | Sali dell'acido gamma-idrossibutirrico ad attivita' ansiolitica e per il trattamento degli stati depressivi |
| IT1266565B1 (it) | 1993-07-22 | 1997-01-09 | Ct Lab Farm Srl | Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico. |
| US5840331A (en) | 1995-06-07 | 1998-11-24 | Arch Development Corporation | Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin |
| IT1283782B1 (it) | 1996-08-09 | 1998-04-30 | Ct Lab Farm Srl | Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo |
| US6495598B1 (en) | 1997-04-22 | 2002-12-17 | Ophtecs Corporation | Perfusate preparation for ophthalmic operation |
| US5990162A (en) | 1997-08-29 | 1999-11-23 | Orphan Medical, Inc. | Method for treatment of fibromyalgia and chronic fatigue syndrome |
| EP1140061B1 (en) | 1998-12-23 | 2003-05-02 | Orphan Medical Inc. | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| AU2001291173A1 (en) | 2000-09-22 | 2002-04-02 | Orphan Medical, Inc. | Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers |
| FR2817256B1 (fr) | 2000-11-27 | 2005-07-15 | Univ Pasteur | Derives de l'acides 4-hydroxybutanoique et de son homologue superieur comme ligands des recepteurs du gamma- hydroxybutyrate (ghb), compositions pharmaceutiques les contenant et utilisations pharmaceutiques |
| WO2006124609A2 (en) * | 2005-05-16 | 2006-11-23 | Joseph Johnson | Methods and compositions for treating arg |
| US8778398B2 (en) * | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
| US8771735B2 (en) | 2008-11-04 | 2014-07-08 | Jazz Pharmaceuticals, Inc. | Immediate release dosage forms of sodium oxybate |
| US8410304B2 (en) | 2009-04-15 | 2013-04-02 | Norac Pharma | Process for preparing gamma-hydroxybutyrate |
| EP2566462B1 (en) * | 2010-05-04 | 2020-07-08 | Jazz Pharmaceuticals Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
| US8591922B1 (en) | 2012-12-14 | 2013-11-26 | Jazz Pharmacuticals, Inc. | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
-
2013
- 2013-01-11 US US13/739,886 patent/US8591922B1/en active Active
- 2013-10-03 US US14/045,673 patent/US9132107B2/en active Active
- 2013-12-13 ES ES13863231.0T patent/ES2660056T3/es active Active
- 2013-12-13 CN CN201380072864.8A patent/CN105025892B/zh active Active
- 2013-12-13 PT PT172025488T patent/PT3335709T/pt unknown
- 2013-12-13 WO PCT/US2013/074954 patent/WO2014093791A1/en active Application Filing
- 2013-12-13 LT LTEP17202548.8T patent/LT3335709T/lt unknown
- 2013-12-13 PL PL13863231T patent/PL2931268T3/pl unknown
- 2013-12-13 EP EP13863231.0A patent/EP2931268B1/en active Active
- 2013-12-13 BR BR112015014007A patent/BR112015014007A2/pt active Search and Examination
- 2013-12-13 IN IN3943CH2015 patent/IN342829B/en unknown
- 2013-12-13 ES ES17202548T patent/ES2827005T3/es active Active
- 2013-12-13 CA CA2894876A patent/CA2894876C/en active Active
- 2013-12-13 TW TW106143923A patent/TWI681770B/zh active
- 2013-12-13 MX MX2015007531A patent/MX366681B/es active IP Right Grant
- 2013-12-13 KR KR1020157018947A patent/KR102180343B1/ko active IP Right Grant
- 2013-12-13 JP JP2015547980A patent/JP6215347B2/ja active Active
- 2013-12-13 HU HUE17202548A patent/HUE051060T2/hu unknown
- 2013-12-13 AU AU2013359114A patent/AU2013359114B2/en active Active
- 2013-12-13 DK DK17202548.8T patent/DK3335709T3/da active
- 2013-12-13 EP EP17202548.8A patent/EP3335709B1/en active Active
- 2013-12-13 SG SG11201504637TA patent/SG11201504637TA/en unknown
- 2013-12-13 DK DK13863231.0T patent/DK2931268T3/en active
- 2013-12-13 TW TW102146274A patent/TWI639425B/zh active
- 2013-12-13 PT PT138632310T patent/PT2931268T/pt unknown
- 2013-12-13 TR TR2018/02271T patent/TR201802271T4/tr unknown
- 2013-12-13 EP EP20190343.2A patent/EP3799867A1/en active Pending
- 2013-12-13 SI SI201331802T patent/SI3335709T1/sl unknown
-
2014
- 2014-02-04 US US14/172,751 patent/US8901173B2/en active Active
- 2014-07-22 NO NO14741895A patent/NO3027826T3/no unknown
-
2015
- 2015-06-11 IL IL239355A patent/IL239355A/en active IP Right Grant
- 2015-08-07 US US14/821,384 patent/US9555017B2/en active Active
-
2016
- 2016-03-18 HK HK16103210.0A patent/HK1215181A1/zh unknown
- 2016-12-20 US US15/385,447 patent/US10195168B2/en active Active
-
2018
- 2018-02-14 CY CY20181100181T patent/CY1119918T1/el unknown
- 2018-12-21 US US16/230,460 patent/US10675258B2/en active Active
-
2020
- 2020-05-12 US US15/930,295 patent/US11554102B2/en active Active
- 2020-10-19 HR HRP20201685TT patent/HRP20201685T1/hr unknown
- 2020-11-02 CY CY20201101030T patent/CY1123498T1/el unknown
-
2021
- 2021-09-20 US US17/479,886 patent/US20220000815A1/en not_active Abandoned
-
2023
- 2023-06-30 US US18/346,015 patent/US20240156759A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201685T1 (hr) | Sastavi gama-hidroksibutirata i njihova upotreba za liječenje poremećaja | |
| HRP20180425T1 (hr) | Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline | |
| MX2016006197A (es) | Formulaciones de compuestos de azaindol. | |
| RS54329B1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING RIFAXIMINE, PROCEDURES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS | |
| RU2017134002A (ru) | Стабильные композиции тетрагидробиоптерина | |
| JP2012031131A5 (hr) | ||
| MX2013014846A (es) | Benzoxazepinonas fusionadas como moduladoras de canales ionicos. | |
| EA201300053A1 (ru) | Фосфатсвязывающий препарат для удобного приема | |
| IL188402A0 (en) | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate | |
| RU2015136849A (ru) | Композиции, содержащие 15-он эпк, и способы их применения | |
| HRP20240166T1 (hr) | Postupak liječenja prader-willijevog sindroma | |
| EA201200616A1 (ru) | Производные 2-оксо-1-пирролидинилимидазотиадиазола | |
| HRP20200642T1 (hr) | Čvrsti obrazac za doziranje koji sadrži mikronizirani citizin | |
| WO2008008592A3 (en) | Multi-particulate formulation having tramadol in immediate and controlled release form | |
| PL402191A1 (pl) | Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję | |
| EA201992382A3 (ru) | Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения | |
| HRP20230762T1 (hr) | Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama | |
| RS53612B1 (en) | SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING IBUPROFEN SALTS | |
| RU2011134414A (ru) | Комбинация фульвовой кислоты для лечения различных состояний и болезней | |
| MX2015012666A (es) | Preparacion de complejo que incluye valsartan y rosuvastatina calcica y metodo de fabricacion para el mismo. | |
| MX2014002673A (es) | 2-(croman-6-iloxi)-tiazoles sustituidos y su uso como productos farmaceuticos. | |
| RU2013127794A (ru) | Фармацевтическая комбинация и композиция для лечения ожирения и ее применение | |
| HRP20161153T1 (hr) | Farmaceutski pripravak koji sadrži aspirin i bisoprolol | |
| PH12015502560A1 (en) | Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease | |
| RU2010154205A (ru) | Твердая лекарственная форма препаратов мемантина и его солей |